ANI· access · memory · existence · Antalya
Horizon Europe · EIC · international funders

The paths that close
can be reopened.

ANI is a niche VR/metaverse access + memory + existence + legacy platform for people of any age whose body, health, means or circumstances cut them off from the world — older, ill, bed-bound, physically disabled, travel- or financially-restricted, isolated. With a VR headset they travel a world they can no longer reach, return to a memory, and exist as their own character alongside other people. We do not promise a cure. We promise comfort, access, scale and personalization — and an honest, measurable pilot. Built in Antalya, Türkiye, for a European consortium.

Why ANI fits EU innovation funding
Türkiye has been a full associated country to Horizon Europe since January 2021 — Turkish organizations can access Cluster 1 (Health), the EIC Accelerator and Eurostars on essentially the same terms as EU member states. ANI sits squarely on Cluster 1's Destination 1 — healthy aging, demographic change, accessibility, digital health — and brings a deployable, personalizable VR pipeline plus a network-effect platform thesis. The decisive thing for a reviewer: every claim is bounded to the evidence. Here, honest framing is not a weakness — it is the trust signal that survives evaluation.

What ANI is

Less a technology than a promise to reopen a closed path.

A person lives as far as they can still go.

At some point the paths begin to close — for some it is age, for others an illness, an accident, a condition present from birth. The world stays where it is, but the road to it is cut. Three kinds of path close: the path to a place (the places you cannot reach), the path to the past (memories slipping away), and the path to a person (bonds breaking). Memories do not fade and people do not move away — the road to them closes. ANI reopens those roads: using Gaussian Splatting, a modern 3D reconstruction technique, we build photorealistic, navigable places from real photographs; with a headset on, a person stands inside that place, looks around, walks through it.

What ANI is NOT: a real-estate / villa tour, a hotel showcase, a trade-fair booth. These are real businesses — but they are the founder's separate archviz skill, the cash infrastructure that funds ANI's R&D, not ANI's identity or revenue wing. To a reviewer this matters: it means the R&D is partly de-risked by non-dilutive founder cash, while the funded project is the access platform itself.

Three pillars

Travel. Remember. Exist.

One pillar for each of the three paths that close.

TRAVEL

"Your body can't go, yet you are there." Experience a world you cannot reach — a sacred journey, a distant city, a museum, the village where you were born — by moving through it from the inside.

REMEMBER

"That moment was not erased; you can return to it." Re-live a memory inside a navigable scene rebuilt from a single old photograph, in a deliberate "dream-cloud" aesthetic.

EXIST

"You are beside someone again." Exist as a character free of the body's limits, meet real people, form a bond — and, if you wish, leave a trace after you.

The heart of the platform

Not synthetic characters — real people.

Most virtual worlds are empty because no one stays in them for long. ANI's thesis is this: access- and travel-restricted people may, out of need, spend many hours here — which can mean an always-live population. The "no critical mass, dead world" problem of other metaverses turns, here, into an advantage. On top of that, people without physical limits — the young, volunteers, researchers, families — find a reason to join. The intended outcome is an intergenerational bridge: a grandchild who cannot visit in person can meet a grandparent in this world. There is early evidence that intergenerational virtual contact may reduce loneliness (IJERPH 2022) — not a proven fact.

Honest boundary: this is a thesis, not a proven fact, and we present it as such. Indeed, RCT meta-analyses of technology-based loneliness interventions have so far found no significant effect, and network size alone is not a defensible moat. The always-live population and the network effect could move ANI from "niche aid tool" to a self-reinforcing, scalable platform — but we present this as a structured hypothesis to be tested in the pilot, not a proven moat; real defensibility likely comes from niche depth + institutional partnerships + ethics/trust + non-copyable content. (Real users, not NPCs: NPC ≠ presence.)

How it works · deployment model

A pipeline that travels to the person.

ANI runs inside a partner's existing care or community settings — no new building, no heavy infrastructure. A portable hardware kit, a short companion-supervised session, and a programmable schedule.

01

Capture & build

Photoreal, navigable scenes reconstructed from a person's own photos via Gaussian Splatting — or a ready-made world to travel to. Where data is sparse, synthetic completion is used: always clearly labeled, never presented as a faithful memory.

02

Session

Seated, short, voluntary, nurse/staff-supervised. A personal memory-place, a guided visit, or a shared social space. Comfort-first profile (no sudden camera, teleport-based movement); the exit/stop protocol is always ready.

03

Scale

Programmable and repeatable: it begins in one setting and, only if pilot data is positive, becomes a multi-site programme. It opens to scale an experience a therapist cannot physically carry from room to room.

Not clinical superiority — comfort, access, scale, personalization.

Why immersive VR

Comfort and access. VR brings a programmable, repeatable, supervised experience to a bed-bound or mobility-limited person in an institution — one no companion could otherwise deliver. Tolerance is documented for short, seated, low-motion sessions. The deliberately soft, "dream-like" look is not a flaw: low fidelity reduces cybersickness and cognitive load. GS is still a maturing technology and we say so.

Why personalization & presence

Scale, the moment that matters, and the live population. A scene built from a person's own life opens a door a generic environment never can — and the same pipeline reproduces it across many settings, faithfully and at cost. The real people inside those scenes are what make it a platform rather than a single-use tool.

Scientific grounding

We are honest, so we are review-ready.

The only frame worthy of a research consortium and its evaluators: where the evidence ends, the claim ends too.

Position
ANI is not a medical treatment. We do not claim to cure dementia, restore memory, or resolve agitation.
Evidence
Reminiscence-based approaches show a moderate-strength benefit to quality of life and mood and are a recommended non-pharmacological approach in long-term care (multiple PRISMA reviews; GRADE low-to-moderate). Immersive VR and virtual tourism are feasible and well-tolerated in older and home-bound adults — within a narrow envelope (short, seated), with ~11% dropping out from cybersickness and not everyone tolerating it (early-stage; PLOS One 2021); no serious adverse events reported. Honestly: the stronger evidence is for reminiscence content — the VR delivery itself remains feasibility-level and must not borrow the content's evidence.
Primary promise
Modest and defensible: in-session positive engagement and an emotional moment — a recognition, a smile, an "I know this place." Clinical effect sizes — including any agitation outcome, framed as a secondary, exploratory aim — will be measured in an ethics-approved pilot, never presented as proven.
Why VR?
Not clinical superiority — comfort, access, scale and personalization. VR delivers, programmably and repeatably, an experience that mobility-limited people in care cannot otherwise reach.
The dream aesthetic
That the scenes are a little hazy, "dream-like", is deliberate, not a defect: low fidelity reduces cybersickness and cognitive load (critical for older users). GS remains an immature technology — dynamic scenes, transparency, scale are open problems — and we do not hide it.
GDPR & ethics alignment. A person's photographs, voice and memories — and any health context — are special-category personal data. ANI is built around this: consent-based and purpose-limited processing, local-first computation where possible, secure storage, and a right to erasure that extends to backups. Synthetic content is never presented as a real memory, and we do not perform a first-person reanimation of the deceased. In Türkiye this is governed by KVKK, the GDPR-aligned national law; IRB/ethics-committee approval precedes any pilot. For a consortium, this means a partner who reduces, rather than adds, regulatory risk.

Digital continuity

The full vision — the decision delegated to those who approve.

The EXIST pillar invites the boldest question: what if a person wished to turn their own digital trace into a legacy that outlives them? We do not hide this vision — we write it out in full — but we do not decide it alone. There is no product about to ship: no layer of ANI goes live without the approval of the relevant institutions, the state, academia and ethics boards. So we put the whole possibility on the table as an option spectrum — from "no continuity axis at all", through a consent-based living digital will, a bereaved-family commemoration model, an evolving digital self, up to an intergenerational living-legacy archive — and we delegate the choice to the approving stakeholders. ANI imposes none of these; the approval chain selects.

Invariant across every option: ANI does not "bring anyone back"; we never say we have digitally resurrected a person. The frame is commemoration / continuity / legacy — labeled and consent-based — never resurrection, never a first-person identity lie, with synthetic content always labeled. For a reviewer this rules deepfake / digital-resurrection reputational risk out from the start.

Consortium & readiness

What is ready — and the partners we seek.

EU research funding is built for multi-country consortia (Horizon Europe Cluster 1 typically requires at least three independent legal entities from three countries). An early-stage SME's realistic role is partner / technology provider / work-package lead — not coordinator. We say this plainly: it is how the consortium gets funded.

Best thematic fit
Horizon Europe Cluster 1 — Destination 1 (aging, demographic change, accessibility, digital health). Programme ≈ €95.5B (2021–2027); Türkiye associated since Jan 2021. (Call topics/deadlines confirmed from the official call text.)
Most accessible step
Eurostars / TÜBİTAK 1709 — a joint R&D project needing only 1 Turkish + 1 foreign SME, with an innovative SME as coordinator. The realistic near-term EU entry.
Single-company route
EIC Accelerator — grant up to €2.5M plus equity up to €10–15M; 2026 budget ≈ €414M. Türkiye has full blended-finance access. Mid-term, once product/clinical maturity is reached.
Bridge instrument
EIT Health — Innovation Validation Call 2026, up to €850,000 (max 50% of project budget). (Turkish direct-eligibility to be confirmed from the call text.)
AAL / aging
AAL2 has no direct successor; AAL-type (ICT + elderly/accessibility) work has moved into Horizon Europe Cluster 1 and EIT Health — where an end-user (care/clinical) partner is near-mandatory.

The ask

Three honest pathways into European funding.

We are not asking a reviewer to believe an overclaim. We are proposing a measurable pilot and a consortium fit, sequenced from most accessible to most ambitious.

PathwayWhat we proposeFit & timing
1. Eurostars / 1709A joint R&D project with one EU SME partner, ANI eligible as an innovative SME, targeting a VR access + memory experience for care and community settings.Most accessible near-term EU step; TÜBİTAK national support in place.
2. Horizon Cluster 1Join an aging / accessibility / digital-health consortium as VR technology provider / WP lead; we help recruit a clinical lead and a care end-user partner via the Türkiye NCP.Destination 1 calls (e.g. HORIZON-HLTH-2026-01; a 2027 neurodegenerative clinical call). Best thematic fit.
3. EIC AcceleratorSingle-company application once clinical evidence and a scalable, network-effect model mature; grant + equity, Türkiye fully eligible for blended finance.Mid-term, product-maturity gated; EIT Health validation can bridge to it.

All programme amounts, topic codes and deadlines must be confirmed from the official call text; the 2027 neurodegenerative call figure (≈ €10M/project) is from a draft work programme and is to be confirmed.

Honesty boundary

Clear to reviewers, clear to families.

ANI is not a medical treatment. We do not claim to cure dementia, restore memory, or resolve agitation — the current evidence does not support such claims, and any agitation outcome is framed as a secondary, exploratory aim to be measured, not a primary promise. Our primary promise is modest and measurable: in-session positive engagement and an emotional moment — dignity and access, treated as a right. Reminiscence-based approaches show a moderate-strength benefit to quality of life; immersive VR is feasible and well-tolerated in older adults (early-stage). The network-effect / live-population claim is a thesis to be proven with pilot and usage data, not a fact. Clinical effects will be measured in an ethics-approved pilot, never presented as proven. Synthetic content is always faithful and clearly labeled; we never claim to "bring anyone back" — we keep a memory, a voice, a place, a bond alive. The full digital-legacy vision is offered as an option spectrum with the decision delegated to approving institutions and ethics boards; nothing goes live without that approval. All processing runs on consent, purpose limitation and the right to erasure (GDPR / KVKK).

"I know this place."

A continent is growing older, and many of its people — at any age — are cut off from the world. The paths that close need not stay closed. We work for the single moment when a person's eyes light up in recognition — and we are ready to measure it, honestly, with the right partners.

ANI · reopen the paths that close: travel, remember, exist — built for a European consortium
ANI is a member of the narchviz R&D family · Antalya, Türkiye ani.narch.tech